3k3a-apc
Recombinant proteinexperimental
Clinical trial activity
4 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2012 (NCT01660230)
Timeline
Indications
Mechanism of action
- Salivary acidic proline-rich phosphoprotein 1/2Supplementation
Salivary acidic proline-rich phosphoprotein 1/2 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- 3k3a-apc
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05484154 | Phase 3 | Apr 30, 2023 | National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, University of South Carolina, University of Southern California, ZZ Biotech, LLC |
| NCT05039268 | Phase 2 | Oct 31, 2021 | Macquarie University, ZZ Biotech, LLC |
| NCT02222714 | Phase 2 | Oct 1, 2014 | Cedars-Sinai Medical Center, Harvard University, National Institute of Neurological Disorders and Stroke (NINDS), University of Iowa, ZZ Biotech, LLC |
| NCT01660230 | Phase 1 | Aug 1, 2012 | Cedars-Sinai Medical Center, ZZ Biotech, LLC |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ZZ Biotech, LLC | For profit | 4 | 3 | 3 | 2012 |
| Cedars-Sinai Medical Center | Academic/Hospital | 2 | 0 | 2 | 2012 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 2 | 0 | 2 | 2014 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Macquarie University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Iowa | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of South Carolina | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Southern California | Academic/Hospital | 1 | 0 | 1 | 2023 |
9 organizations
Page 1 / 1